Outline
The invention relates to new deuterated morphine derivatives of general formula (I), and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixtures of enantiomers or combinations thereof, as well as polymorphs, tautomers, solvates, salts, esters and prodrugs thereof, furthermore to a process for the preparation thereof, and to pharmaceutical compositions comprising them. The principal aim of the present invention is the provision of compounds with higher receptor binding affinity resulting in improved pharmacological properties for example in higher analgesic and antitussive activity, with longer duration of action and reduced adverse effects through the administration of lower doses, and additionally with a reduced risk of the possibility of drug abuse.